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Background: Musculin (MSC) is a basic helix-loop-helix transcription factor that inhibits myogenesis during normal
development and contributes to the differentiation defect in rhabdomyosarcoma. As one of many transcription
factors that impede myogenesis, its binding on a genome-wide scale relative to the widespread binding of the
myogenic factor MyoD is unknown.
Methods: Chromatin immunoprecipitation coupled to high-throughput sequencing was performed for endogenous
MSC in rhabdomyosarcoma cells and its binding was compared to that of MyoD in the same type of cells.
Results: MSC binds throughout the genome, in a pattern very similar to MyoD. Its binding overlaps strongly with
regions enriched for acetylated histone H4, as well as regions that score high for DNase hypersensitivity in human
myoblasts. In contrast to MyoD, MSC has a more relaxed binding sequence preference in the nucleotides that flank the
core E-box motif.
Conclusions: The myogenic inhibitor MSC binds throughout the genome of rhabdomyosarcoma cells, in a pattern
highly similar to that of MyoD, suggesting a broad role in buffering the activity of MyoD in development and
rhabdomyosarcomas.
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The advent of high-throughput sequencing coupled to
chromatin immunoprecipitation (ChIP-seq) has permit-
ted the global assessment of DNA binding of numerous
transcription factors. While some factors show a rela-
tively restricted binding pattern near their regulated
genes, others bind widely throughout the genome [1].
The basic helix-loop-helix (bHLH) gene MyoD, a key
regulator for the specification and differentiation of skel-
etal muscle [2], shows widespread binding at tens of
thousands of genomic locations [3]. In addition to dir-
ectly regulating the transcription of genes associated* Correspondence: stapscot@fhcrc.org
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distribution, and reproduction in any mediumwith a subset of the locations it binds, MyoD binding
also results in histone acetylation at its binding sites
throughout the genome, demonstrating a biological con-
sequence of its genome-wide binding [3].
The myogenic activity of MyoD can be inhibited by a
variety of transcription factors, including other members
of the bHLH protein family [4]. Inhibitory mechanisms
take a variety of forms, including competition for protein
partners [5,6], the occlusion of MyoD binding sites and
transcriptional repression after DNA binding [7,8], and
binding to MyoD itself [9]. Musculin (MSC) is a small
bHLH inhibitor that functions with a variety of mecha-
nisms. Like MyoD, MSC forms heterodimers with
E-proteins. The MSC:E-protein heterodimer binds to
E-boxes and inhibits myogenic reporters and MyoD-
mediated myogenesis [10]. The activity of MSC is quite
complex, however, with a critical role in the specificationntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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niofacial muscles in mice [11], possibly through regula-
tion of the expression of members of the myogenic
regulatory factor (MRF) family such as MyoD and Myf5
[12]. A similar, crucial role in craniofacial muscle devel-
opment has been seen in zebrafish models [13], and the
Drosophila ortholog of musculin is required for the spe-
cification of certain gut muscle cells [14]. There is also
evidence that musculin is not restricted to expression in
skeletal muscle and functions to affect the differentiation
of non-myogenic cells [15-17]. Together these studies
indicate that musculin might have either positive or
negative activities in gene transcription depending on a
variety of factors and cellular context.
Recently, we have shown that MSC competes with
MyoD for the available pool of E-proteins in rhabdo-
myosarcoma cells [18], and that it occludes MyoD bind-
ing sites, interfering with myogenic activation [19].
Rhabdomyosarcoma (RMS) is a pediatric tumor of skel-
etal muscle that fails to undergo terminal myogenic dif-
ferentiation properly. These tumors express MyoD [20]
and many also express MSC [18]. Since the tumors ap-
pear to represent an arrested state of development of
normal muscle cells undergoing the transition from pro-
liferative myoblasts to terminally differentiated myotubes
[18,19], this makes RMS cells an ideal system for com-
paring the binding of MSC and MyoD and further eluci-
dating the ability of MSC to function as an inhibitor of
differentiation.
We have previously performed ChIP-seq for MyoD in
a cell culture model of embryonal RMS, RD cells [21],
and we now report a genome-wide assessment of MSC
binding in RD cells. Strikingly, MSC binds widely
throughout the genome, in an overlapping but non-
identical pattern to MyoD, reflecting an overlapping but
not identical E-box sequence specificity. The substantial
direct overlap of MSC and MyoD sites together with the
close proximity of many MSC- and MyoD-specific sites
suggests that MSC has the potential for broadly modu-
lating MyoD activity in normal development and in
rhabdomyosarcomas.Methods
Cell culture and construct preparation
RD cells were obtained from the American Type Culture
Collection (ATCC), and all analyses were performed on
cells that originated from low passage number frozen ali-
quots. RD cells were maintained in DMEM with 10%
bovine calf serum and 1% Pen-Strep (Gibco). MSC with
a tandem affinity purification (TAP) tag was constructed
by cloning the coding sequence for MSC in-frame with a
TAP-tagged pBabe plasmid so that the TAP tag is N-
terminal to MSC.Chromatin immunoprecipitation and ChIP-seq
Chromatin immunoprecipitation (ChIP) was performed
in RD cells with an approach that has been described
previously [3]. Antibodies used were as follows: MyoD
[22], MSC (Santa Cruz, sc-9556X). Quantitative PCR
(qPCR) was performed using SybrGreen from Bio-Rad
on an Applied Biosystems 7900HT. Enrichment was cal-
culated as the percentage of input in samples with anti-
body divided by the percentage of input in matched
samples without antibody. Primer sequences for site-
specific confirmatory ChIP were as follows: A – f:
gcttgatgatgcttgcagaa r: cggagaggatcatgtaactgc; B – f:
ctggtccctttcaggagaca r: gccgtccatctaaaggtcaa; C – f: aat
gacaagcactcgcacaa r: atcgagaagttgcgtgcttt; D – f: atctg
gaatgccttctgtgg r: attgcctaggaagggacaca; E – f: gcgac
gagctccacatctac r: aggatgcccatgactttgag; F – f: ctcaccatcc
gaccaagagt r: ggggtcacgtgtgtatgaga.
Liquid chromatography and mass spectrometry
The isolation of complexes associated with TAP-tagged
MSC was performed identically to prior experiments
[18], but MSC-associated complexes were only purified
singly through tobacco etch virus (TEV)-mediated elu-
tion. Peptides were digested with trypsin before loading
on a ThermoFinnigan LTQ FT and undergoing liquid
chromatography coupled to tandem mass spectrometry
(LC-MS/MS). The data were searched using X!Comet.
Electrophoretic mobility shift assays
Shift assays were performed as described previously [23].
Proteins were transcribed and translated in vitro from
CS2-based plasmids using a rabbit reticulocyte lysate kit
(Promega). Probe sequences were as follows (forward se-
quences only listed, reverse complement sequences not
shown): MSC-specific: cggccgaccagctggagatcct; -1 pos-
ition mutation (mut): cggccgagcagctggagatcct; -1/+1 pos-
ition mut: cggccgagcagctgcagatcct; MSC-specific T mut:
cggccgtccagctggagatcct; -1/+1 T mut: cggccgtgcagctgca-
gatcct; CG E-box: cggccgaccacgtggagatcct; B1:
gatccccccaacacctgctgcctga.
Peak calling
Sequences were extracted by GApipeline-0.3.0. Reads
mapping to the X and Y-chromosomes were excluded
from our analysis. Reads were aligned using BWA to the
human genome (hg19). Duplicate sequences were dis-
carded to minimize the effects of PCR amplification.
Each read was extended in the sequencing orientation to
a total of 200 bases to infer the coverage at each gen-
omic position. Peak calling was performed by an in-
house developed R package, which models background
reads by a negative binomial distribution as previously
described [24]. Peaks in the MyoD and MSC samples
that overlapped with peaks in the RD no antibody cell-
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were removed from the analysis.
Motif analysis
We applied an in-house developed Bioconductor pack-
age motifRG for discriminative de novo motif discovery
as previously described [3,25]. To find discriminative
motifs for MSC-specific peaks, we selected MSC-specific
and MSC- and MyoD-shared peaks. Specific peaks were
defined as peaks present for one transcription factor
with a P value cutoff of 10-10 and absent for the other
with a P value cutoff of 10-4. Shared peaks were present
for both factors with a P value cutoff of 10-10.
P value peak overlap analysis
We adopted a nonparametric rank-based paradigm to
compare two ChIP-seq samples as previously described
[24]. We ranked all peaks by their P values and grouped
ranks into bins of 3,000 (that is, the top 3,000 peaks,
then the top 6,000 peaks, and so on). Then we computed
the fraction of top x peaks in a sample that overlap with
the top y peaks in another sample, where x and y vary
from 3,000 to 30,000, and y is equal to or greater than x.
Results
Musculin and MyoD have overlapping, but non-identical,
genome-wide binding patterns
To compare the binding pattern of the bHLH myogenic
inhibitor MSC to that of the myogenic activator MyoD,
ChIP-seq for endogenous MSC was performed in RD
cells under growth conditions. MSC binds at a compar-
able number of sites as MyoD and with a similar gen-
omic distribution, although there was a slightly greater
enrichment of MSC binding in the region surrounding
the transcription start site (TSS) compared to MyoD
(Table 1), possibly reflecting the GC-rich nature of pro-
moters and the preferred MSC E-box (see below). As
with MyoD, MSC was found to bind widely at regions
outside of those generally thought of as gene related,
binding to a high degree (approximately 40% of all sites)Table 1 Number and genomic location of musculin and MyoD
Factor Number of peaks Genomic location (fraction of pe
P value cutoffb Promoterc Proximal promoterd
10-5 10-7 10-10
Musculin 54901 39036 25688 0.165 0.231
MyoD [21] 50320 35203 24501 0.110 0.175
aThe fraction of MyoD and musculin peaks found in each listed type of genomic re
peak may be included in multiple categories.
bThree P value cutoffs were used to evaluate whether ChIP-seq reads are considere
c+/−500 bp from the transcription start site (TSS).
d+/−2 kb from the TSS.
e+/−500 nucleotides from the end of the transcript.
f–2 kb to −10 kb upstream of the TSS.
g+2 kb to +10 kb from the end of the transcript.
h>10 kb from any annotated gene.in intergenic regions. A number of sites identified as be-
ing specifically and strongly enriched for either MyoD or
MSC by ChIP-seq were tested with biologically inde-
pendent site-specific ChIP, and factor-specific enrich-
ment in agreement with the ChIP-seq data found at all
sites (Additional file 1: Figure S1).
MSC heterodimerizes with E-proteins to bind to E-
boxes [10], and we have previously shown by LC-MS/
MS that the E-protein E12 associates with MSC in RD
cells, while MyoD does not associate with MSC [18]. To
further confirm that the ChIP-seq data represent distinct
MyoD or MSC bHLH dimers, a TAP-tagged MSC was
created. This was shown to maintain biological activity
as measured by its ability to repress myogenic reporters
and bind E-boxes in electrophoretic mobility shift assays
(EMSAs) (data not shown). The tagged MSC was then
introduced stably into RD cells through retroviral trans-
duction and MSC-associated complexes pulled down
and subjected to LC-MS/MS. As expected, all E-proteins
were found to associate with MSC, while there was no
indication of a MSC: MyoD interaction (Additional file
2: Table S1).
A motif analysis of the binding site preferred by MSC
found strong enrichment for binding at a GC core
E-box (Figure 1A, top), one of the two E-box cores we
previously identified as being preferred by MyoD
(Figure 1A, bottom). In contrast to MyoD, MSC exhibits
a strong nucleotide preference for a ‘G’ at the first
nucleotide after the E-box (CAGCTGG), designated
position +1 relative to the E-box. Also notable was a dif-
ference in the sequences enriched at the two positions
immediately before the E-box, designated positions −1
and −2 relative to the E-box. We have previously shown
that MyoD:E and NeuroD2:E heterodimers show a
flanking preference for G or A in the −1 and −2 posi-
tions [3,24], whereas the MSC motif does not demon-
strate a similarly strong preference at these positions
(Figure 1A, positions 2 and 3).
As anticipated from the motif analysis, MyoD and
MSC showed overlapping but not identical bindingChIP-seq peaks in RD cells
aks)a
3 Primee Exon Intron Upstreamf Downstreamg Intergenich
0.029 0.204 0.563 0.209 0.170 0.423
0.027 0.154 0.560 0.187 0.164 0.405
gion are given. Note that categories are not mutually exclusive, and a single
d a ‘peak’ and included in the count of the total number of peaks.
Figure 1 MSC has similar, but non-identical, DNA binding characteristics to MyoD and binds at many of the same genomic locations.
(A) E-box motif enrichment of MSC and MyoD bound sites in RDs identifies a similar preference for central dinucleotide identity (GC and GG), but
differing preferences in the E-box flanking nucleotides. (B) Comparison of the top 30,000 MyoD and MSC peaks in RDs demonstrates substantial
overlap in the sites bound by each factor. Peaks were ranked by P value, and grouped into bins that increase by 3,000 peaks each time (that is,
first the 3,000 most significant peaks are considered, than the 6,000 most significant, and so on). The fraction of the overlap is indicated by color,
as depicted in the legend. (C) De novo motif analysis of peaks specific to MSC identifies an 8 bp motif (row 2) enriched at MSC-specific binding
sites. The motif analysis compared MSC-specific binding sites to those sites that bound both MyoD and MSC. bp, base pair; fg.frac, bg.frac: fraction
of foreground/background sequences that contain at least one motif occurrence; MSC, musculin; ratio, enriched/depleted ratio of motifs.
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assigned to sequential cumulative bins of 3,000 peaks
based on rank by P value and the percentage overlap
ranged from approximately 40% to 80% (Figure 1B). A
motif analysis of sites that were found to bind only MSC
(MSC-specific) in comparison to sites bound either
solely by MyoD (MyoD-specific) or by both MyoD and
MSC (shared) identified a strong enrichment for C at
the −1 position and G at the +1 position, giving an 8-bpmotif of CCAGCTGG (Figure 1C). Examination of the
ChIP-seq data at specific loci identified sites bound only
by one of the factors, sites bound by both factors in an
apparently identical pattern, and sites bound by each
factor in closely overlapping but non-identical binding
patterns (Figure 2). The closely overlapping but distinct
patterns suggests each factor is binding to a distinct E-
box in the region; however, this is identified as an ‘over-
lap’ in the analysis shown in Figure 1B.
Figure 2 MyoD and MSC bind at unique identical and overlapping but non-identical sites in the genome. MSC and MyoD have both
unique and overlapping binding patterns at various sites in the genome. Screenshots are shown from the UCSC Genome browser for MyoD and
MSC ChIP-seq results at four distinct genomic locations (indicated below each panel, representing positions in hg19). The identity of the bHLH
factor is indicated along the left, and E-boxes are represented as black marks along the bottom of each panel. Note that the number of MyoD
reads in the ‘MSC only’ panel is five, in contrast to 298 reads for MSC, and are not centered on an E-box, and thus do not likely represent true
MyoD binding. bHLH, basic helix-loop-helix; ChIP-seq, chromatin immunoprecipitation coupled to high-throughput sequencing; MSC, musculin.
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genomic regions and regions with higher levels of
histone acetylation
We have previously shown that MyoD binding induces
histone acetylation at binding sites throughout the gen-
ome [3]. To test the hypothesis that the genome-wide
binding of MSC might inhibit acetylation in either a glo-
bal manner or at some subset of MyoD-bound locations,
we performed ChIP-seq for acetylated histone H4
(AcH4) from RD cells under conditions similar to the
MyoD and MSC ChIP-seq data. AcH4 enrichment was
examined at peaks identified as MSC-specific, MyoD-
specific and shared. Surprisingly, the highest levels of
AcH4 enrichment showed a stronger association with
MSC peaks, both MSC specific and shared (Figure 3A).
This trend became even more evident when peaks were
grouped based on distance from the nearest gene TSS.
While MyoD-specific peaks showed essentially identical
AcH4 enrichment regardless of their location relative to
a TSS, MSC-specific and shared peaks showed a strong
shift to higher AcH4 enrichment at peaks located closerto a TSS (<2 kb from the nearest TSS) (P value of the
difference between MSC-specific and MyoD-specific
peaks: 1 × 10-45, P value for MSC-specific versus shared
peaks: 1 × 10-7) (Figure 3B). MSC binding did not cor-
relate, either positively or negatively, with genes that we
have previously identified as being differentially regu-
lated in RD cells compared to normal myogenic cells
[21] (data not shown).
Given the lack of a global effect on gene expres-
sion, we hypothesized that the association with AcH4
might simply reflect binding of MSC at regions of
open chromatin. The MyoD-specific, MSC-specific
and shared peaks in the RD cells were compared to
publicly available DNase hypersensitivity data from
human myoblasts. Shared peaks had the highest
proportion of peaks that overlapped with DNase
hypersensitive sites (shared: approximately 80%,
MSC-specific: approximately 70%, MyoD-specific: ap-
proximately 50%) (Figure 3C), and this relation held
across the entire range of hypersensitive values
(Additional file 3: Figure S2A).
Figure 3 MSC binding is associated with open chromatin. (A) Sites bound by MyoD and MSC are associated with acetylated histones.
ChIP-seq for acetylated histone H4 (AcH4) was performed in RD cells and density plots constructed to compare the square root of the AcH4 value
at all sites bound by MSC, MyoD or both factors. (B) MSC-specific and MyoD/MSC shared peaks are associated with higher levels of AcH4 near
the transcription start site (TSS) of genes compared to MyoD-specific peaks. Density plots were constructed as in (A) for categories of peaks first
split by peak identity (MyoD, MSC, shared), then subcategorized on distance from the nearest TSS. (C) Sites bound by MSC in RD cells overlap
with DNase hypersensitive (HSS) sites in normal human myoblasts. Publicly available DNase HSS data from human myotubes were compared to
the sites bound by MyoD and MSC in RD cells. Data for each factor category (for example, MSC-specific) are plotted as the fraction of peaks that
overlap with locations that have a signal in the HSS data (that is, the graphed fraction = 1 – fraction of peaks at HSS score of ‘0’). AcH4, acetylated
histone H4; bHLH, basic helix-loop-helix; ChIP, chromatin immunoprecipitation; ChIP-seq, chromatin immunoprecipitation coupled to high-
throughput sequencing; HSS, hypersensitive; K, thousands of bp; MSC, musculin; TSS, transcription start site.
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low level of association with hypersensitive sites, but
subcategorizing the MyoD-specific peaks based on
whether they were unique to RD cells, or common to
RDs and human myotubes [21] revealed that common
peaks were generally associated with hypersensitive sites,
and peaks unique to RDs were not (Additional file 3:
Figure S2B). We have previously shown that differences
in MyoD binding between myotubes and RD cells can
be correlated with differences in E-box accessibility be-
tween the cell types [21]. This suggests that the MyoD
peaks specific to RMS, that is, not present in primary
skeletal muscle cells, represent binding by MyoD to E-
boxes that are normally inaccessible to bHLH binding in
primary muscle cells and were therefore not identified aslying in HSS regions in the primary muscle cell dataset.
Taken as a whole, the above data identify MSC binding
as largely occurring in the context of areas of open and
accessible chromatin.
Musculin dimers have less restrictive binding site
preferences at flanking nucleotides than MyoD dimers
Electrophoretic mobility shift assays with in vitro trans-
lated proteins were performed to further investigate the
sequence preference of MyoD and MSC dimers using
the sequence from a MSC-specific peak at the SKI gene
that contained the MSC-specific consensus 8-bp motif
(CCAGCTGG). Shifts comparing binding of MyoD:E
and MSC:E heterodimers demonstrated that MSC het-
erodimers could bind to the 8-bp motif or a probe in
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(−1 mut), making it more reflective of the core MSC
motif from Figure 1A (Figure 4A, compare lane 4 to 5).
Binding of MSC to a probe in which both −1 (‘C’ to ‘G’)Figure 4 MSC dimers have relaxed requirements for flanking sequenc
protein heterodimers do not bind well to MSC-specific sequences, but bind
shift assays (EMSAs) were performed using in vitro translated proteins and
judging by their relative mobility, small amounts of E-protein homodimers.
equally well by competitors with variations in their flanking sequence, whil
subjected to competition by excesses of cold probes as indicated. 25× and
Variations in competitor sequences are indicated, and ‘CG Ebox’ refers to a
all binding of MyoD and MSC. (C) Single nucleotide changes in flanking se
missive of MSC dimer binding. Shift assays were performed using proteins
two lanes, with one lane having a probe with ‘A’ in the −2 position relative
position, as indicated in red. All shifts were performed using a sufficient ex
shown in 4A and 4B). All probe counts were quantitated before addition to
Negative control lanes indicate lanes where probes were tested with an in
EMSA, electrophoretic mobility shift assay; MSC, musculin.and +1 (‘G’ to ‘C’) had been changed (−1/+1 mut) still
occurred, but at reduced levels (Figure 4A, compare
lanes 4 and 5 to 6). In contrast, the ability of MyoD:E
heterodimers to form complexes improved as the probee compared to MyoD dimers. (A) MyoD homodimers and MyoD:E-
after a small number of sequence changes. Electrophoretic mobility
probes as indicated. The asterisks indicate the location of what are,
(B) MSC heterodimers can be competed off a preferred binding site
e MyoD heterodimers cannot. MyoD:E and MSC:E heterodimers were
50× refer to the excess mass of cold probe relative to hot probe.
probe with an inverted central dinucleotide sequence that abolishes
quence can completely abrogate MyoD dimer binding, but still be per-
and probes as indicated. Each type of dimer combination was run in
to the E-box, and the other lane having a probe with ‘T’ in that
cess of probe so that visible free probe was present for all lanes (not
ensure there were roughly equivalent amounts in all compared lanes.
vitro translated empty CS2 vector to identify any non-specific binding.
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compare lane 10 to 12). Taken together with the motif
analysis identifying the differences at positions −1 and
−2, this suggests that the sequence preference for dimer
binding is more stringent for dimers containing MyoD
than those containing MSC, even with a common dimer
partner. Similar results were observed with homodimers
of both MSC and MyoD, though both types of homodi-
mers formed more weakly compared to their heterodi-
mer counterparts (Figure 4A, compare lane 1 to 3 and 7
to 9, data not shown).
To further test this hypothesis, competition assays
were performed on MSC and MyoD heterodimers. As
expected, MSC was competed off the MSC-specific 8-bp
motif equally well by cold competitors with the consen-
sus 8-bp motif, –1 mut, or −1/+1 mut (Figure 4B, left
panel, compare lanes 3 and 4 to 5 and 6, and to 7 and
8), suggesting relatively similar affinity. MSC was not
competed with a sequence in which the core nucleotides
of the E-box were inverted to a ‘CG’ from ‘GC’
(Figure 4B, left panel, compare lanes 9 and 10 to 2), dem-
onstrating sequence specificity of the competition assays.
In contrast, MyoD heterodimers were only effectively
competed by sequences at which it had formed visible
complexes (Figure 4B, right panel, compare lanes 16 and
17 to 12 and 13, and to 14 and 15), and even a single
nucleotide change had a notable impact on competition
(compare −1/+1 mut to −1 mut). As with MSC, MyoD:E
heterodimers failed to form on the CG core E-box (data
not shown).
In addition to the relaxed preference at the positions
immediately flanking the E-box, relative to MyoD, MSC
also exhibited a sharp difference in response to sequence
changes at the −2 position. The inclusion of a ‘T’ at the −2
position is permissive for MSC heterodimer binding
(Figure 4C, compare lane 3 to 4), but absolutely abolishes
binding of MyoD heterodimers (Figure 4C, compare lane
7 to 8), with similar results seen with the homodimers
(Figure 4C, compare lane 1 to 2 and 5 to 6).
Discussion
Our genome-wide comparison of the DNA binding
characteristics of MyoD and MSC reveals that, even
though MSC is one of multiple myogenic inhibitors and
might be expected to bind at only a subset of all MyoD
binding locations, it binds at a comparable number of
sites as MyoD, with a similar, but non-identical binding
site preference. Even though MSC heterodimerizes with
the same E-proteins as MyoD and shares the same se-
quence preference at the central dinucleotide of E-
boxes, it has less sequence preference for the positions
that flank E-boxes than other bHLH dimers we have re-
ported [3,24]. It should be noted that the electrophoretic
mobility shift assays were performed using in vitrotranslated proteins, and thus would not reflect the effect
of any post-translational modifications that may occur
in vivo. However, the in vitro binding preferences reflect
those preferences seen in the in vivo ChIP-seq results.
Additionally, work with other bHLH factors has demon-
strated excellent correlation between binding sites iden-
tified by ChIP-seq and binding seen with EMSA [24].
Overall, the broad overlap of MyoD and MSC binding
indicates a potential for MSC to buffer the binding and
activity of MyoD broadly, as well as other E-box binding
factors.
We have previously shown that MSC can inhibit
MyoD-mediated activation of myogenic targets by oc-
cluding specific E-boxes [19], in addition to competing
for a limiting pool of E-proteins [18]. We have proposed
that this activity controls the growth-versus-
differentiation decision point in myogenic cells, serving
as a component of interlocking oscillating regulatory cir-
cuits that keep myogenic cells balanced between prolif-
eration and terminal differentiation [19].
This model suggests that the relationship between
bHLH proteins and target sites is highly dynamic, in
which dimers form and dissociate, from both their pro-
tein partners and DNA binding sites, resulting in a fluc-
tuating expression of gene targets. In turn, some subset
of such targets feed back on the process to regulate
growth and differentiation appropriately. MSC has a very
similar core binding motif as MyoD dimers but a greater
degree of flexibility for flanking nucleotides, which could
reflect a lower need for tight regulation of the specific E-
boxes MSC can bind to compared to MyoD and be the
mechanism by which MSC acts to broadly sequester E-
proteins and occupy potential MyoD binding sites.
Other factors have also been suggested as having an in-
hibitory function during myogenesis by binding at E-
boxes [26,27], further potentially increasing the complex
nature of the interplay occurring at bHLH binding sites.
The similar core motif requirements for MyoD and
MSC ensure that MSC binds at many sites regulated by
MyoD, and the +1 ‘G’ preference of the MSC motif in-
creases the likelihood of it targeting E-boxes located in
GC-rich gene promoter regions. While the gene regula-
tion analysis did not identify a global role in gene sup-
pression, MSC does modulate MyoD activity at the
myogenic microRNA miR-206 [19], and it may have a
similar role at many other MyoD regulated genes, an ef-
fect that would not be discernible with our current
analysis.
This model also offers possible insight into the ability
of MSC to serve apparently as either a positive or nega-
tive regulator of transcription. With a component of
MSC’s repressive activity appearing to be through inter-
ference with DNA binding by other bHLH factors, MSC
activity could be substantially different depending on the
MacQuarrie et al. Skeletal Muscle 2013, 3:26 Page 9 of 10
http://www.skeletalmusclejournal.com/content/3/1/26individual cellular context, potentially interfering with
the binding of inhibitory complexes. It is not known
what histone modification enzymes MSC might recruit,
nor is it clear how MSC activity would differ depending
on the extent of competition by other bHLH proteins
for binding partners and sites, and these additional pa-
rameters might contribute to a context-specific ability to
serve as a positive or negative regulator.
Both the finding that MSC is associated with regions
enriched for acetylated histone H4 in RD cells and
DNase hypersensitive sites in normal myotubes suggests
MSC generally binds at areas of open chromatin. It is
unclear at this point why the notable enrichment is seen
at sites closest to transcription start sites (<2 kb), though
it is possible that part of this enrichment is due to the
GC-rich nature of promoters and the binding site prefer-
ence of MSC for an additional flanking ‘G’ compared to
MyoD (Figure 1). While an effect by MSC on histone
acetylation cannot be formally ruled out, mass spectrom-
etry data did not identify any association with histone
acetyltransferases (KLM, unpublished observations), sug-
gesting that, in skeletal muscle cells, MSC is opportunis-
tic in binding to areas of open chromatin, rather than
instructing changes in chromatin structure. This would
be consistent with the model proposed above, serving to
assist MSC acting in a role as a dynamic competitor of
MyoD function in the differentiation of skeletal muscle.
Conclusions
The myogenic bHLH inhibitor musculin binds widely
throughout the genome in RD rhabdomyosarcoma cells
and has a broadly overlapping, but non-identical, set of
binding sites and peaks as MyoD. Compared to the pre-
ferred MyoD E-box sequence, MSC has slightly less
stringency for flanking sequence preference, permitting
binding to a slightly broader set of E-boxes and poten-
tially overlapping with other bHLH factors. Together
with prior studies showing the ability of MSC to modu-
late MyoD activity at overlapping sites at specific pro-
moters, these results suggest a broad potential for MSC
to modulate the activity of MyoD, and perhaps other
bHLH proteins, during normal development and in
cancers.
Additional files
Additional file 1: Figure S1. MyoD and MSC site-specific ChIP confirms
the ChIP-seq results. Biologically independent site-specific ChIP was per-
formed at three sites indicated by the ChIP-seq to be MyoD-specific bind-
ing sites, three sites indicated as MSC-specific, and one control location
with no significant binding of either factor, as indicated by both the chart
and the screenshots. The enrichment was calculated for each location as
the percentage of input amplified in qPCR with antibody divided by the
percentage of input amplified with no antibody, and the value is indi-
cated at the top of each bar. Note that the y-axis is non-linear.Screenshots are from the UCSC genome browser, and the identity of the
factor used in the ChIP, and the number of reads at the peak of occu-
pancy are indicated along the side. ChIP, chromatin immunoprecipitation;
ChIP-seq, chromatin immunoprecipitation coupled to high-throughput
sequencing; MSC, musculin.
Additional file 2: Table S1. LC-MS/MS identification of MSC-associated
transcription factors in RD cells.
Additional file 3: Figure S2. MSC binds sites associated with DNase
hypersensitivity, and MyoD peaks found only in RD cells, not in normal
myotubes, are associated with areas identified in myotubes as DNase-
resistant. (A) Shared MyoD and MSC binding peaks are associated
strongly with DNase hypersensitive (HSS) sites in human myoblasts. The
overlap between ChIP-seq peaks and HSS data is graphed for the entirety
of the range of HSS values. Values for a DNase signal of ‘0’ are equal to 1
– the fraction graphed in Figure 3C. The data are plotted as a cumulative
distribution function, where a value on the y-axis represents the fraction
of data that has a value equal to or less than the corresponding x-axis
DNase HSS value. (B) MyoD-specific sites bound by MyoD only in RD cells,
and not in human myotubes, overlap poorly with HSS sites in human
myotubes. The MyoD-specific peaks from Figure 3C and (A) were further
grouped into those peaks that were found both in RD cells and normal
human myotubes (RD/myotube shared), and those found only in RD cells
(RD-specific). As in Figure 3C, the data for each category (for example,
RD-specific) are plotted as the fraction of peaks that overlap with sites
that have some signal in the HSS data (that is, the graphed fraction = 1 –
fraction of peaks at HSS score of ‘0’). ChIP-seq, chromatin immunoprecipi-
tation coupled to high-throughput sequencing; HSS, hypersensitive; MSC,
musculin.
Abbreviations
AcH4: acetylated histone H4; bHLH: basic helix-loop-helix; bp: base pair;
ChIP: chromatin immunoprecipitation; ChIP-seq: chromatin
immunoprecipitation coupled to high-throughput sequencing;
EMSA: electrophoretic mobility shift assay; HSS: hypersensitivity; kb: kilobase;
LC-MS/MS: liquid chromatography coupled to tandem mass spectrometry;
MRF: myogenic regulatory factor; MSC: musculin; mut: mutation;
qPCR: quantitative PCR; RMS: rhabdomyosarcoma; TAP: tandem affinity
purification; TEV: tobacco etch virus; TSS: transcription start site.
Competing interests
The authors declare they have no potential competing interests.
Authors’ contributions
KLM contributed to all experimental designs, performed all non-
computational experiments and drafted the manuscript. ZY performed the
ChIP-seq and all other computational analyses and contributed to both ex-
perimental design and data interpretation. APF performed the RD cell-type
control ChIP-seq. SJT conceived the project, contributed to all experimental
designs and edited the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
KLM was supported by a Developmental Biology Predoctoral Training Grant
(T32HD007183). ZY was supported by the NIH Interdisciplinary Training Grant
in Cancer Research (T32CA080416). APF was supported by a grant from the
University of Washington Child Health Research Center (NIH
U5K12HD043376-10) and Hyundai Hope on Wheels. SJT was supported by
NIH NIAMS (R01AR045113).
Author details
1Human Biology Division, Fred Hutchinson Cancer Research Center, 1100
Fairview Ave N C3-168, Seattle WA 98109, USA. 2Molecular and Cellular
Biology Program, University of Washington, Seattle WA 98105, USA. 3Clinical
Research Division, Fred Hutchinson Cancer Research Center, Seattle WA
98109, USA. 4Department of Pediatrics, University of Washington School of
Medicine, Seattle WA 98105, USA. 5Department of Neurology, University of
Washington, Seattle WA 98105, USA.
Received: 17 March 2013 Accepted: 10 October 2013
Published: 1 November 2013
MacQuarrie et al. Skeletal Muscle 2013, 3:26 Page 10 of 10
http://www.skeletalmusclejournal.com/content/3/1/26References
1. MacQuarrie KL, Fong AP, Morse RH, Tapscott SJ: Genome-wide
transcription factor binding: beyond direct target regulation. Trends
Genet 2011, 27:141–148.
2. Davis RL, Weintraub H, Lassar AB: Expression of a single transfected cDNA
converts fibroblasts to myoblasts. Cell 1987, 51:987–1000.
3. Cao Y, Yao Z, Sarkar D, Lawrence M, Sanchez GJ, Parker MH, MacQuarrie KL,
Davison J, Morgan MT, Ruzzo WL, Gentleman RC, Tapscott SJ: Genome-
wide MyoD binding in skeletal muscle cells: a potential for broad cellular
reprogramming. Dev Cell 2010, 18:662–674.
4. Berkes CA, Tapscott SJ: MyoD and the transcriptional control of
myogenesis. Semin Cell Dev Biol 2005, 16:585–595.
5. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H: The protein Id: a
negative regulator of helix-loop-helix DNA binding proteins. Cell 1990,
61:49–59.
6. Spicer DB, Rhee J, Cheung WL, Lassar AB: Inhibition of myogenic bHLH
and MEF2 transcription factors by the bHLH protein Twist. Science 1996,
272:1476–1480.
7. St-Pierre B, Flock G, Zacksenhaus E, Egan SE: Stra13 homodimers repress
transcription through class B E-box elements. J biol chem 2002,
277:46544–46551.
8. Lemercier C, To RQ, Carrasco RA, Konieczny SF: The basic helix-loop-helix
transcription factor Mist1 functions as a transcriptional repressor of
myoD. EMBO J 1998, 17:1412–1422.
9. Hamamori Y, Wu HY, Sartorelli V, Kedes L: The basic domain of myogenic
basic helix-loop-helix (bHLH) proteins is the novel target for direct inhib-
ition by another bHLH protein, Twist. Mol Cell Biol 1997, 17:6563–6573.
10. Lu J, Webb R, Richardson JA, Olson EN: MyoR: a muscle-restricted basic
helix-loop-helix transcription factor that antagonizes the actions of
MyoD. Proc Natl Acad Sci USA 1999, 96:552–557.
11. Lu J-R, Bassel-Duby R, Hawkins A, Chang P, Valdez R, Wu H, Gan L, Shelton
JM, Richardson JA, Olson EN: Control of facial muscle development by
MyoR and capsulin. Science 2002, 298:2378–2381.
12. Moncaut N, Cross JW, Siligan C, Keith A, Taylor K, Rigby PW, Carvajal JJ:
Musculin and TCF21 coordinate the maintenance of myogenic
regulatory factor expression levels during mouse craniofacial
development. Development 2012, 139:958–967.
13. Lee GH, Chang MY, Hsu CH, Chen YH: Essential roles of basic helix-loop-
helix transcription factors, capsulin and musculin, during craniofacial
myogenesis of zebrafish. Cell Mol Life Sci 2011, 68:4065–4078.
14. Ismat A, Schaub C, Reim I, Kirchner K, Schultheis D, Frasch M: HLH54F is
required for the specification and migration of longitudinal gut muscle
founders from the caudal mesoderm of Drosophila. Development 2010,
137:3107–3117.
15. Hishikawa K, Marumo T, Miura S, Nakanishi A, Matsuzaki Y, Shibata K,
Ichiyanagi T, Kohike H, Komori T, Takahashi I, Takase O, Imai N, Yoshikawa M,
Inowa T, Hayashi M, Nakaki T, Nakauchi H, Okano H, Fujita T: Musculin/
MyoR is expressed in kidney side population cells and can regulate their
function. J Cell Biol 2005, 169:921–928.
16. Yu L, Sangster N, Perez A, McCormick PJ: The bHLH protein MyoR inhibits
the differentiation of early embryonic endoderm. Differentiation 2004,
72:341–347.
17. Yu L, Mikloucich J, Sangster N, Perez A, McCormick PJ: MyoR is expressed
in nonmyogenic cells and can inhibit their differentiation. Exp Cell Res
2003, 289:162–173.
18. Yang Z, MacQuarrie KL, Analau E, Tyler AE, Dilworth FJ, Cao Y, Diede SJ,
Tapscott SJ: MyoD and E-protein heterodimers switch rhabdomyosar-
coma cells from an arrested myoblast phase to a differentiated state.
Genes Dev 2009, 23:694–707.
19. MacQuarrie KL, Yao Z, Young JM, Cao Y, Tapscott SJ: miR-206 integrates
multiple components of differentiation pathways to control the
transition from growth to differentiation in rhabdomyosarcoma cells.
Skeletal Muscle 2012, 2:7.
20. Saab R, Spunt SL, Skapek SX: Chapter 7 – myogenesis and
rhabdomyosarcoma: the Jekyll and Hyde of skeletal muscle. Current Top
Dev Biol Cancer Dev 2010, 94:197–234.
21. MacQuarrie KL, Yao Z, Fong AP, Diede SJ, Rudzinski ER, Hawkins DS,
Tapscott SJ: Comparison of genome-wide binding of MyoD in normal hu-
man myogenic cells and rhabdomyosarcomas identifies regional and
local suppression of pro-myogenic transcription factors. Mol Cell Biol
2013, 33:773–784.22. Tapscott SJ, Davis RL, Thayer MJ, Cheng PF, Weintraub H, Lassar AB: MyoD1:
a nuclear phosphoprotein requiring a Myc homology region to convert
fibroblasts to myoblasts. Science 1988, 242:405–411.
23. Davis RL, Cheng PF, Lassar AB, Weintraub H: The MyoD DNA binding
domain contains a recognition code for muscle-specific gene activation.
Cell 1990, 60:733–746.
24. Fong AP, Yao Z, Zhong JW, Cao Y, Ruzzo WL, Gentleman RC, Tapscott SJ:
Genetic and epigenetic determinants of neurogenesis and myogenesis.
Dev Cell 2012, 22:721–735.
25. Palii CG, Perez-Iratxeta C, Yao Z, Cao Y, Dai F, Davison J, Atkins H, Allan D,
Dilworth FJ, Gentleman R, Tapscott SJ, Brand M: Differential genomic tar-
geting of the transcription factor TAL1 in alternate haematopoietic line-
ages. EMBO J 2011, 30:494–509.
26. Genetta T, Ruezinsky D, Kadesch T: Displacement of an E-box-binding re-
pressor by basic helix-loop-helix proteins: implications for B-cell specifi-
city of the immunoglobulin heavy-chain enhancer. Mol Cell Biol 1994,
14:6153–6163.
27. Soleimani VD, Yin H, Jahani-Asl A, Ming H, Kockx CE, van Ijcken WF, Grosveld
F, Rudnicki MA: Snail regulates MyoD binding-site occupancy to direct
enhancer switching and differentiation-specific transcription in myogen-
esis. Mol Cell 2012, 47:457–468.
doi:10.1186/2044-5040-3-26
Cite this article as: MacQuarrie et al.: Genome-wide binding of the basic
helix-loop-helix myogenic inhibitor musculin has substantial overlap
with MyoD: implications for buffering activity. Skeletal Muscle 2013 3:26.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
